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Dual antiplatelet therapy, comprising aspirin and a P2Y12
receptor inhibitor, is firmly established for the secondary
prevention of thrombotic events with the rationale that they
inhibit thromboxane A2- (TxA2) and ADP-P2Y12-dependent
pathways of platelet activation, respectively. We have recently
reported that strong P2Y12 receptor blockade alone, however,
can provide inhibition of platelet aggregation to a broad range
of agonists that is not further enhanced by aspirin [1].While the
clinical relevance of these observations is unclear, we have
speculated that administration of aspirin to individuals achiev-
ing sufficiently strong P2Y12 receptor blockade, has the
potential to produce effects secondary to inhibition of cyclo-
oxygenase at non-platelet sites, without providing additional
antithrombotic activity [2]. The degree of P2Y12 pathway
blockade that is achieved in clinical practice, however, is quite
variable [3], reflecting both the choice of drug and large inter-
individual differences in drug metabolism [4]. Here, we have
extended our previous observations of the interactions between
aspirin and strong P2Y12 blockade [1] by considering what
additional anti-aggregatory effects aspirin provides when only
partial P2Y12 blockade is achieved, whichmay better reflect the
clinical reality of these drugs.
We measured aggregation responses of platelet-rich plasma
(PRP), using 96-well plate light transmission aggregometry, as
previously described [1]. Blood was collected by venepuncture
into tri-sodium citrate (0.32% final) from healthy volunteers
who had abstained from non-steroid anti-inflammatory drug
consumption for 14 days. To model the effects of P2Y12
blockade and cyclo-oxygenase inhibition in vitro, PRP was
incubated with the irreversible thienopyridine P2Y12 inhibitor,
prasgurel-active metabolite (PAM; 0.1–10 lmol L)1), the
reversible, cyclo-pentyl-triazolo-pyrimidine P2Y12 antagonist,
ticagrelor (0.1–10 lmol L)1) and/or aspirin (1–100 lmol L)1)
for 30 min at 37 C before addition of the agonist. Additional
methodological details are provided as online supplementary
information.
Using this approach we determined the inhibitory potencies
of ticagrelor, PAMand aspirin against aggregations induced by
ADP (0.625–20 lmol L)1), the thromboxane-mimetic U46619
(0.1–30 lmol L)1) and arachidonic acid (0.1–1 mmol L)1).
Both ticagrelor and PAM caused concentration-dependent
inhibition of aggregations induced by ADP (Fig. S1), with
ticagrelor displaying greater potency than PAM (log IC50
values for inhibition of aggregation to 20 lmol L)1 ADP:
ticagrelor, )6.46; PAM, )5.64). Notably, the potency of
ticagrelor, but not PAM, varied with the concentration of ADP
(e.g. log IC50 values for inhibition of aggregation to
2.5 lmol L)1 ADP: ticagrelor, )7.05; PAM, )5.63). Aspirin,
at concentrations up to 100 lmol L)1, was without significant
effect upon ADP-induced aggregations. Ticagrelor and PAM,
but not aspirin, produced complete, concentration-dependent
inhibition of platelet aggregations induced byU46619 (Fig. S2)
with similar potency as for inhibition of ADP-induced
aggregations (log IC50 values for inhibition of aggregation to
30 lmol L)1 U46619; ticagrelor, )6.24; PAM, )5.25). This is
consistent with earlier reports that the second, irreversible wave
of platelet aggregation that follows TP receptor activation is
dependent upon platelet-derived ADP acting upon platelet
P2Y12 receptors [5]. Ticagrelor and PAM, as well as aspirin,
also produced complete, concentration-dependent inhibitions
of platelet aggregations induced by AA (Fig. S3; log IC50
values for inhibition of aggregation to 1 mmol L)1 AA:
ticagrelor, )6.88; PAM, )6.00; aspirin, )5.20). When the
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production of TxA2 accompanying platelet aggregation
induced by AA was measured (by immunoassay for the levels
of TxB2), ticagrelor, PAM and aspirin were all found to cause
concentration-dependent reductions in TxA2 formation
(Fig. S3; log IC50 values for inhibition of aggregation to
1 mmol L)1 AA: ticagrelor, )6.88; PAM, )5.985; aspirin,
)5.51). This is in agreement with our early findings [1,6], and
indicates that P2Y12 receptors are important in supporting
both the activation mechanisms of platelets that drive TxA2
formation and pathways downstream of the TP receptor.
To explore further the interactions between P2Y12 receptors
and the TxA2 system in platelets, we examined the effect of
aspirin on aggregation induced by a range of agonists in the
presence of concentrations of ticagrelor or PAM producing
different degrees of partial P2Y12 blockade. From the inhibitor
curves to ADP described above, concentrations of ticagre-
lor showing approximate IC5 (0.03 lmol L
)1), IC10
(0.1 lmol L)1), IC50 (0.3 lmol L
)1) and IC90 effects
(3 lmol L)1) were combined with 30 lmol L)1 aspirin, a
concentration approximately equivalent to the peak plasma
levels following ingestion of a 75–100 mg dose of aspirin. In
these experiments, responses to AA (Fig. 1A) were found to be
completely inhibited by ticagrelor at the higher two concen-
trations (representing IC50 and IC90 for ADP-induced
aggregation) without the need for aspirin. The lower two
concentrations of ticagrelor (representing IC5 and IC10 for
ADP-induced aggregation) also produced substantial, but
incomplete, inhibitions (Table S1). Ticagrelor also inhibited
aggregations induced byADP, collagen, epinephrine, the PAR-
1 activating peptide, TRAP-6 (SFLLRN-amide) and U46619,
in a concentration-dependent manner (Fig. 1).
When applied alone, aspirin inhibited aggregations induced
by AA (Fig. 1A), collagen (Fig. 1C) and epinephrine
(Fig. 1D), and showed a weak effect against ADP (Fig. 1B)
but did not alter aggregations induced by TRAP-6 (Fig. 1E) or
U46619 (Fig. 1F). In contrast, aspirin did augment the anti-
aggregatory effects of the lower three concentrations of
ticagrelor (achieving incomplete P2Y12 inhibition) against both
collagen (Fig. 1C) and epinephrine (Fig. 1D). In the presence
of the highest tested concentration of ticagrelor (3 lmol L)1;
IC90 for ADP-induced aggregation), aspirin provided no
additional anti-aggregatory effects to those of ticagrelor against
aggregations to any agonist (Fig. 1). In agreement with earlier
experiments, production of TxA2 induced by either AA
(Fig. 1G) or collagen (Fig. 1H) was partially inhibited by
0.3 lmol L)1 ticagrelor (IC50 for ADP-induced aggregation)
and abolished by 3 lmol L)1 ticagrelor (IC90 for ADP-
induced aggregation). We have previously reported that TxA2
production in response to epinephrine is inhibited by P2Y12
blockade in the same manner for AA and collagen [1]. Aspirin
(30 lmol L)1) either alone or in combination with ticagrelor
also completely inhibited TxA2 production to either agonist
(Fig. 1G,H). A similar pattern of results was obtained using
equivalent inhibitory concentrations of PAM in place of
ticagrelor (Table S2), and when the concentration of aspirin
was increased to 120 lmol L)1 (Tables S1 and S2).
These studies show that ticagrelor and PAM inhibit platelet
aggregation induced by a range of platelet agonists through a
mechanism consistent with blockade of platelet P2Y12
receptors and that ticagrelor is more potent than PAM in this
regard. As well as inhibiting aggregation following from direct
activation of P2Y12 receptors by the addition of exogenous
ADP, ticagrelor and PAM inhibited aggregations resulting
from stimulation of platelets with AA, a response which is well
characterized as being TxA2 dependent. In addition to
inhibiting platelet responses to endogenously produced TxA2,
ticagrelor and PAM also inhibited the production of TxA2 by
platelets [6]. Interestingly, ADP itself is a poor stimulus for
TxA2 production [1], suggesting that released ADP, acting on
the P2Y12 receptor, acts to potentiate the stimulation of TxA2
synthesis by other signaling pathways activated in parallel.
These results are consistent with the idea that whereas aspirin
may inhibit just the TxA2-dependent pathway of platelet
activation, ticagrelor and PAM can inhibit both the
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Fig. 1. Concentration-response curves for the inhibition by combinations
of ticagrelor (0.3 or 3 lmol L)1) and aspirin (30 lmol L)1) of platelet
aggregations induced by (A) arachidonic acid (AA), (B) ADP, (C) colla-
gen, (D) epinephrine, (E) TRAP-6 or (F) U46619, and of platelet TxB2
formation induced by (G) AA and (H) collagen. n = 4.
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ADP-P2Y12-dependent and the TxA2-dependent pathways of
platelet aggregation. The observation that aspirin adds anti-
aggregatory effects to partial, but not complete, P2Y12 receptor
blockade, further supports this idea.
Taken together these results demonstrate that rather than
ADP-P2Y12 and TxA2 pathways acting independently, the
TxA2-dependent pathway is dependent upon the ADP-P2Y12
pathway both for the production of TxA2 and fundamentally
for the irreversible aggregation that follows activation of TP
receptors. If these data accurately model the situation in vivo,
this may have important implications for the use of dual
antiplatelet therapy using potent P2Y12 antagonists in clinical
practice [2]. For example, one could postulate that addition of
aspirin could produce side-effects secondary to inhibition of
cyclo-oxygenase at non-platelet sites, as has recently become
apparent for non-steroid anti-inflammatory drugs, while pro-
viding little additional anti-aggregatory effect [7,8]. Clearly, the
validity of this hypothesis remains to be determined by clinical
studies.
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Figure S1. Concentration-response curves for the inhibition by
(A) ticagrelor (0.1–10 lmol L)1), (B) prasugrel active metab-
olite (PAM; 0.1–10 lmol L)1) and (C) aspirin (1–
100 lmol L)1) of platelet aggregation induced by ADP
(0.625–20 lmol L)1). n = 4.
Figure S2. Concentration-response curves for the inhibition by
(A) ticagrelor (0.1–10 lmol L)1), (B) prasugrel active metab-
olite (PAM; 0.1–10 lmol L)1) and (C) aspirin (1–
100 lmol L)1) of platelet aggregation induced by U46619
(0.1–30 lmol L)1). n = 4.
Figure S3. Concentration-response curves for the inhibition by
(A, B) ticagrelor (0.1–10 lmol L)1), (C, D) prasugrel active
metabolite (PAM; 0.1–10 lmol L)1) and (E, F) aspirin (1–
100 lmol L)1) of platelet aggregation (A, C, E) and TxA2
release (B, D, F; measured as TxB2) induced by arachidonic
acid (AA; 0.03–1 mmol L)1). n = 4.
Table S1. Area under the concentration-response curve sum-
mary data for the effect of combinations of ticagrelor (0.03, 0.1,
0.3 and 3 lmol L)1) and aspirin (30 and 120 lmol L)1) on
platelet aggregation (A–C) and platelet TxA2 release (D;
measured as TxB2).
Table S2. Area under the concentration-response curve sum-
mary data for the effect of combinations of prasugrel-active
metabolite (PAM; 0.5, 1, 2 and 10 lmol L)1) and aspirin (30
and 120 lmol L)1) on platelet aggregation (A–C) and platelet
TxA2 release (D; measured as TxB2).
Please note:Wiley-Blackwell are not responsible for the content
or functionality of any supporting materials supplied by the
authors. Any queries (other than missing material) should be
directed to the corresponding author for the article.
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